一分钟看懂
这是一项关于卵巢癌的II 期研究，登记的药物或干预包括RC48+carboplatin±bevacizumab，当前状态为招募中。登记地点显示中国北京有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
RC48+carboplatin±bevacizumab · II 期
登记条件中文摘要
年龄范围：18岁至75岁
登记的基本范围为女性，年龄18岁至75岁；以下仅摘录8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Hong Zheng · 北京
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Female subjects aged from 18 to 75 years old;
- * Pathology confirmed the diagnosis of primary epithelial ovarian/fallopian tube/peritoneal carcinoma;
- * Previous treatment lines ≥1 and ≤4, first-line treatment may include maintenance therapy after complete clinical or pathological response;Previously not receiving targeted HER2 drug therapy (including monoclonal antibodies and ADC drugs)
- * Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 at trial entry;
- * Disease must be measurable by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1);
- * Estimated life expectancy of more than 3 months;
- * Local laboratory confirmed HER2 expression: IHC 1+, 2+, or 3+; Subjects were able to provide samples of the primary or metastatic site of the tumor for HER2 detection（Paraffin blocks, paraffin embedded sections or fresh tissue sections ）
- * Adequate haematological, hepatic and renal functions defined by the protocol;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06420973；登记信息更新于 2026-10-01；本站同步于 2026-10-08。